The results have added a strength to the uptrend. Expectations on revenue and earnings per share were met. GNC has already multiplied 1.5 times over the last two years but the strength is not abating. Even after such an amazing growth the P/E is less than 19, and it is trading at 1.79 times sales. Price to book is a little high at 4.98. The forward P/E (fye Dec 31, 2014) is 13.57 and the PEG (5 year) is 0.81. This indicates expectations of future growth. No wonder, several analysts have upgraded the stock. The debt on books remains a concern ($1.1 billion) with high D/E ratio of 123. To maintain the growth story, GNC has to keep bringing novel products in the market. Smaller companies launch great products from time to time and GNC would do well to take advantage of the innovation happening in the market. If smaller companies can do it, GNC can obviously do it better. A small company ChromaDex (CDXC)'s recently launched an energy drink PURENERGY which contains its proprietary ingredient pterostilbene in combination with Caffeine. The combination helps achieve the same energy levels as achieved with energy drinks containing several times the dose of caffeine. Barry Honig increased his stake in the company after the launch. The good work in the last quarter has to be continued. For the quarter ending Mar 31, the revenues and net income grew by 6.5% and 13.8% respectively (yoy). It reported revenue of $664 million and the EPS came at $0.73 (0$.59 yoy). Gross margins were 38.5% and the net margins for the quarter were 10.9%. The net profit margin on a ttm basis is in excess of 10%. Revenue estimates for the next quarter and year are ~$674 million and $2.66 billion respectively. EPS estimates are $0.74 and $2.80 for the next quarter / full year respectively.